HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
210 patients around the world
Available in Puerto Rico, United States, Mexico
This phase 2b, double-blind, randomized, placebo-controlled, multicenter study will evaluate
the effect of HTD1801, 1250 mg twice daily (BID) compared to placebo BID on histologic
improvements in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have
type 2 diabetes mellitus or pre-diabetes.
The study will enroll approximately 210 subjects with biopsy-confirmed non-alcoholic
steatohepatitis and evidence of stage 2 or stage 3 liver fibrosis. Subjects will receive
investigational product for up to 60 weeks.
HighTide Biopharma Pty Ltd
4Research sites
210Patients around the world
This study is for people with
Fatty liver/nash
Nonalcoholic steatohepatitis
Diabetes
Diabetes mellitus type 2
Prediabetes
Requirements for the patient
To 75 Years
All Gender
Medical requirements
Sites
Centro de Investigación y Gastroenterología
Durango No 49 Interior 401, Colonia Roma Norte, Alcaldía Cuauhtemoc, Ciudad de México
Phylasis Clinicas Research - PCR - Toluca
C. Sor Juana I. de La C. 103, 5 de Mayo, 50090 Toluca de Lerdo
IDON S.C Instituto de Diabetes, Obesidad y Nutricion
Calle 5 de mayo #400. Col. El empleado. Cuernavaca. Morelos
FDI Clinical Research
Recruiting
998 Av. Luis Muñoz Rivera, San Juan, 00927
StudyCENTRICITY
SponsorHighTide Biopharma Pty Ltd
Conditions
Nonalcoholic steatohepatitisDiabetes mellitus type 2Prediabetes